Clinical trials: doxorubicin hydrochloride, active
Cardiotoxicity
Cardioprotection Effect of Linagliptin
1. Background and Rationale Breast cancer is one of the most common malignancies affecting women worldwide and represents a major health burden in Egypt.
- Trial name
- Linagliptin (NCT07852546)
- Testing
- Doxorubicin, Empaglifloz 5 mg orally once daily
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Tanta University
Lymphoblastic Leukemia in Children
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.
- Trial name
- SR ALL (NCT06099366)
- Testing
- induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate, Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate, Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
- Where
- 13 sites in South Korea
- Volunteers
- 116 people
- Sponsor
- Hee Young Ju
Gastric Cancer
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Gastric cancer remains a significant global public health problem. Although in developed countries its incidence has dramatically decreased, on a worldwide scale it is still a leading cause of cancer-related deaths.
- Trial name
- TOPGEAR (NCT01924819)
- Testing
- Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel, Preoperative chemoradiotherapy, Gastric resection
- Where
- 59 sites in Australia, Belgium and 8 more
- Volunteers
- 574 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Peritoneal Carcinomatosis, Gastric Cancer
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients.
- Trial name
- GASPACCO (NCT04595929)
- Testing
- Staging laparoscopy, 5-Fluorouracil, Leucovorin
- Where
- Russia
- Volunteers
- 304 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Richter Syndrome
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
The STELLAR trial will assess the effect of acalabrutinib taken in combination with CHOP-R compared to taking CHOP-R alone in patients with newly diagnosed Richter's Syndrome (RS).
- Trial name
- STELLAR (NCT03899337)
- Testing
- Acalabrutinib, Cyclophosphamide, Doxorubicin
- Where
- 17 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Birmingham
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
Lurbinectedin + Doxorubicin In Leiomyosarcoma
This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with…
- Conditions
- Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
- Trial name
- NCT05099666
- Testing
- Lurbinectedin, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore…
- Trial name
- NCT00572169
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Arkansas
Ovarian Neoplasms, Endometrial Neoplasms
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer
- Trial name
- DOVE (NCT06023862)
- Testing
- Dostarlimab, Bevacizumab, Doxorubicin
- Where
- 27 sites in Australia, Hong Kong and 5 more
- Volunteers
- 198 people
- Sponsor
- Yonsei University
Advanced Leiomyosarcoma
A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy
This study is a prospective single arm multicenter intervention study aimed at evaluating the feasibility of using organoid drug sensitivity results to guide first-line treatment of advanced leiomyosarcoma.
- Trial name
- LMS-HOPE (NCT07405346)
- Testing
- treatment based on the results of drug sensitivity analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Myeloma
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have…
- Trial name
- NCT00871013
- Testing
- Melphalan, Velcade, Thalidomide
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Arkansas
Glioblastoma Multiforme, Relapse
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide.
- Trial name
- NCT06356883
- Testing
- IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Université de Sherbrooke
Hodgkin Lymphoma
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD').
- Trial name
- NCT06831370
- Testing
- Brentuximab Vedotin, Doxorubicin, Vinblastine
- Where
- 11 sites in India
- Volunteers
- 124 people
- Sponsor
- Takeda
Desmoid
Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis
Desmoid fibromatoses are rare (1-2 cases/million per year) and locally aggressive mesenchymal tumors. For asymptomatic disease, current guidelines suggest an initial period of active surveillance.
- Trial name
- Embodesmo (NCT06268457)
- Testing
- Chemoembolization with Doxorubicin
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Ortopedico Rizzoli
Soft Tissue Sarcoma
Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
The primary aim of this study is to determine the utility of TOPO2A as a biomarker for sensitivity to doxorubicin or its derivatives.
- Trial name
- NCT04055753
- Testing
- Doxil, Doxorubicin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Hodgkin Lymphoma
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult…
- Trial name
- NCT07551583
- Testing
- Nivolumab, Doxorubicin Hydrochloride, Vinblastine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Triple Negative Breast Cancer
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes…
- Trial name
- NCT04437160
- Testing
- Epirubicin or Pirarubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Chinese Academy of Medical Sciences
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT05929768
- Testing
- Biospecimen Collection, Carboplatin, Cyclophosphamide
- Where
- 963 sites in United States, Mexico and 1 more
- Volunteers
- 2,400 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Cardiotoxicity
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
This is an observational study for patients with breast cancer that will be treated with doxorubicin (Adriamycin) and/or trastuzumab (Herceptin).
- Conditions
- Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
- Trial name
- CCT2 (NCT05078190)
- Testing
- Social Determinants of Health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Empgliflozin Cardioprotective Effect
Cardioprotective Effect of Empagliflozin in Breast Cancer Patients
Background: Doxorubicin (DOX) remains a cornerstone in adjuvant and neoadjuvant therapy for breast cancer, but its utility is hindered by dose-dependent cardiotoxicity.
- Trial name
- NCT07815808
- Testing
- Empagliflozin (EMPA), Metformin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Stage III Breast Cancer, Stage IIIA Breast Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative…
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- InCITe (NCT03971409)
- Testing
- Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib
- Where
- 12 sites in United States
- Volunteers
- 145 people
- Sponsor
- Laura Huppert, MD, BA